loading
Precedente Chiudi:
$843.47
Aprire:
$840.055
Volume 24 ore:
535.13K
Relative Volume:
0.65
Capitalizzazione di mercato:
$85.22B
Reddito:
$14.92B
Utile/perdita netta:
$4.42B
Rapporto P/E:
20.17
EPS:
41.0422
Flusso di cassa netto:
$3.79B
1 W Prestazione:
+4.22%
1M Prestazione:
+8.82%
6M Prestazione:
+5.11%
1 anno Prestazione:
+45.93%
Intervallo 1D:
Value
$825.83
$841.54
Intervallo di 1 settimana:
Value
$779.08
$859.34
Portata 52W:
Value
$541.00
$859.34

Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile

Name
Nome
Regeneron Pharmaceuticals Inc
Name
Telefono
(914) 847-7000
Name
Indirizzo
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Name
Dipendente
15,410
Name
Cinguettio
@regeneron
Name
Prossima data di guadagno
2026-10-27
Name
Ultimi documenti SEC
Name
REGN's Discussions on Twitter

Compare REGN vs VRTX, ARGX, MRNA, RVMD

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
REGN icon
REGN
Regeneron Pharmaceuticals Inc
827.72 85.11B 14.92B 4.42B 3.79B 41.04
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
546.12 136.93B 12.34B 4.34B 3.71B 16.87
ARGX icon
ARGX
Argen X Se Adr
1,033.15 64.95B 4.16B 1.29B 734.26M 19.58
MRNA icon
MRNA
Moderna Inc
145.55 53.23B 2.23B -3.19B -1.60B -8.1462
RVMD icon
RVMD
Revolution Medicines Inc
210.02 45.38B 742.00K -1.37B -1.07B -7.0731

Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2026-03-31 Ripresa Piper Sandler Overweight
2026-03-06 Iniziato Barclays Overweight
2026-01-07 Aggiornamento BofA Securities Underperform → Buy
2025-12-03 Downgrade Morgan Stanley Overweight → Equal-Weight
2025-11-24 Iniziato HSBC Securities Buy
2025-11-24 Ripresa Truist Buy
2025-11-13 Iniziato Scotiabank Sector Perform
2025-08-14 Iniziato Rothschild & Co Redburn Buy
2025-06-30 Downgrade Argus Buy → Hold
2025-05-30 Downgrade RBC Capital Mkts Outperform → Sector Perform
2025-05-30 Downgrade Wells Fargo Overweight → Equal Weight
2025-05-14 Aggiornamento Citigroup Neutral → Buy
2025-04-22 Ripresa Cantor Fitzgerald Overweight
2025-02-05 Aggiornamento Leerink Partners Market Perform → Outperform
2025-01-16 Downgrade UBS Buy → Neutral
2024-12-10 Ripresa BofA Securities Underperform
2024-11-15 Iniziato Wolfe Research Outperform
2024-11-14 Iniziato Citigroup Neutral
2024-09-24 Downgrade Leerink Partners Outperform → Market Perform
2024-03-12 Iniziato Bernstein Outperform
2024-01-12 Aggiornamento RBC Capital Mkts Sector Perform → Outperform
2023-11-09 Iniziato Deutsche Bank Hold
2023-11-03 Aggiornamento Raymond James Mkt Perform → Outperform
2023-08-21 Aggiornamento Canaccord Genuity Hold → Buy
2023-08-21 Reiterato Oppenheimer Perform
2023-06-28 Downgrade Canaccord Genuity Buy → Hold
2023-03-27 Aggiornamento SVB Securities Market Perform → Outperform
2023-03-24 Aggiornamento Jefferies Hold → Buy
2023-03-23 Aggiornamento Raymond James Underperform → Mkt Perform
2023-01-30 Aggiornamento Cowen Market Perform → Outperform
2023-01-20 Aggiornamento JP Morgan Neutral → Overweight
2022-10-26 Downgrade Raymond James Mkt Perform → Underperform
2022-10-17 Downgrade Evercore ISI Outperform → In-line
2022-09-09 Aggiornamento Jefferies Underperform → Hold
2022-09-09 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2022-07-25 Downgrade SVB Leerink Outperform → Mkt Perform
2022-07-13 Iniziato Cantor Fitzgerald Neutral
2022-06-06 Iniziato Jefferies Underperform
2022-05-23 Iniziato SVB Leerink Outperform
2022-01-05 Downgrade BofA Securities Neutral → Underperform
2022-01-03 Aggiornamento Bernstein Mkt Perform → Outperform
2021-12-15 Downgrade Bernstein Outperform → Mkt Perform
2021-12-09 Ripresa Wells Fargo Overweight
2021-12-07 Ripresa Cowen Market Perform
2021-12-06 Iniziato Goldman Buy
2021-11-19 Ripresa BMO Capital Markets Outperform
2021-11-05 Downgrade The Benchmark Company Buy → Hold
2021-06-29 Iniziato H.C. Wainwright Buy
2021-01-25 Aggiornamento BMO Capital Markets Market Perform → Outperform
2021-01-13 Aggiornamento The Benchmark Company Hold → Buy
2021-01-08 Aggiornamento Citigroup Neutral → Buy
2020-10-05 Aggiornamento Cantor Fitzgerald Neutral → Overweight
2020-08-20 Downgrade The Benchmark Company Buy → Hold
2020-07-09 Aggiornamento SunTrust Hold → Buy
2020-05-26 Aggiornamento Wells Fargo Equal Weight → Overweight
2020-04-28 Downgrade Citigroup Buy → Neutral
2020-04-17 Aggiornamento The Benchmark Company Hold → Buy
2020-04-08 Iniziato The Benchmark Company Hold
2020-03-31 Iniziato Wolfe Research Peer Perform
2020-02-27 Iniziato Barclays Overweight
2020-02-26 Aggiornamento Canaccord Genuity Hold → Buy
2020-02-26 Downgrade Robert W. Baird Outperform → Neutral
2020-02-25 Aggiornamento Jefferies Hold → Buy
2020-02-11 Aggiornamento Argus Hold → Buy
2019-12-24 Iniziato Raymond James Mkt Perform
2019-12-16 Downgrade Evercore ISI Outperform → In-line
2019-12-13 Aggiornamento Credit Suisse Neutral → Outperform
2019-11-12 Iniziato SunTrust Hold
2019-11-07 Aggiornamento Citigroup Neutral → Buy
2019-10-17 Ripresa BofA/Merrill Neutral
2019-09-23 Aggiornamento Guggenheim Neutral → Buy
Mostra tutto

Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie

pulisher
06:15 AM

Regeneron stock holds near lofty levels as class action risk emerges - AD HOC NEWS

06:15 AM
pulisher
Sep 06, 2026

REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before September 14, 2026 Deadline - TMX Newsfile

Sep 06, 2026
pulisher
Sep 06, 2026

Regeneron stock slips on a $85.2 billion market value - AD HOC NEWS

Sep 06, 2026
pulisher
Sep 05, 2026

Regeneron Pharmaceuticals, Inc. (REGN) Investors: September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit - Eastern Progress

Sep 05, 2026
pulisher
Sep 04, 2026

Atopic Dermatitis Drugs Market Set to Reach USD 33.42 Billion by 2035, at a CAGR of 7.70% - GlobeNewswire Inc.

Sep 04, 2026
pulisher
Sep 04, 2026

Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch

Sep 04, 2026
pulisher
Sep 04, 2026

Robbins LLP Urges REGN Investors to Contact the Firm Before - GlobeNewswire

Sep 04, 2026
pulisher
Sep 04, 2026

Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now? - The Motley Fool

Sep 04, 2026
pulisher
Sep 04, 2026

Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now? - The Motley Fool

Sep 04, 2026
pulisher
Sep 04, 2026

Biotech Stocks To Watch TodaySeptember 4th - MarketBeat

Sep 04, 2026
pulisher
Sep 04, 2026

SEPTEMBER 14, 2026 REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces - Business Wire

Sep 04, 2026
pulisher
Sep 03, 2026

Beyond the genome: Regeneron’s Abecasis on scaling drug discovery with genetic data - biocentury.com

Sep 03, 2026
pulisher
Sep 03, 2026

Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch

Sep 03, 2026
pulisher
Sep 03, 2026

Regeneron stock steadies after strong Q2 figures and pipeline focus - AD HOC NEWS

Sep 03, 2026
pulisher
Sep 03, 2026

REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law - GlobeNewswire

Sep 03, 2026
pulisher
Sep 03, 2026

REGN Investor Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action NoticeContact SueWallSt - Morningstar

Sep 03, 2026
pulisher
Sep 03, 2026

REGN Stockholders Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire

Sep 03, 2026
pulisher
Sep 02, 2026

REGN 12-DAY DEADLINE ALERT: Regeneron Pharmaceuticals, Inc. - GlobeNewswire

Sep 02, 2026
pulisher
Sep 02, 2026

REGN Deadline Alert: Levi & Korsinsky Reminds Regeneron Pharmaceuticals (REGN) Investors of Securities Class Action Deadline on September 14, 2026 - Morningstar

Sep 02, 2026
pulisher
Sep 02, 2026

Regeneron Pharmaceuticals stock hits 52-week high at $847.60 By Investing.com - Investing.com Nigeria

Sep 02, 2026
pulisher
Sep 02, 2026

Regeneron Pharmaceuticals stock hits 52-week high at $847.60 - Investing.com

Sep 02, 2026
pulisher
Sep 02, 2026

Here’s How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years - Benzinga

Sep 02, 2026
pulisher
Sep 02, 2026

Bronstein, Gewirtz & Grossman LLC Urges Regeneron - GlobeNewswire

Sep 02, 2026
pulisher
Sep 02, 2026

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire

Sep 02, 2026
pulisher
Sep 02, 2026

Regeneron Pharmaceuticals Stock: Is REGN Outperforming the Healthcare Sector? - Barchart.com

Sep 02, 2026
pulisher
Sep 02, 2026

Why Did Regeneron Pharmaceuticals (REGN) Climb After Its Latest Update? - simplywall.st

Sep 02, 2026
pulisher
Sep 01, 2026

Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch

Sep 01, 2026
pulisher
Sep 01, 2026

Portnoy Law Firm Announces Class Action on Behalf of Regeneron Pharmaceuticals, Inc. Investors - GlobeNewswire

Sep 01, 2026
pulisher
Sep 01, 2026

Regeneron stock gains after steady 2026 growth and legal action reminder - AD HOC NEWS

Sep 01, 2026
pulisher
Aug 31, 2026

Is Pasatru’s Rare Disease Approval With Home Infusion Potential Altering The Investment Case For Regeneron Pharmaceuticals (REGN)? - simplywall.st

Aug 31, 2026
pulisher
Aug 31, 2026

REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Aug 31, 2026
pulisher
Aug 31, 2026

REGN Shareholder Alert: Regeneron Pharmaceuticals, Inc. - GlobeNewswire

Aug 31, 2026
pulisher
Aug 31, 2026

REGN 2-WEEK DEADLINE ALERT: Regeneron Pharmaceuticals, Inc. - GlobeNewswire

Aug 31, 2026
pulisher
Aug 31, 2026

Regeneron stock draws investor interest as class action lawsuit and strong earnings frame the outloo - AD HOC NEWS

Aug 31, 2026
pulisher
Aug 30, 2026

REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Aug 30, 2026
pulisher
Aug 30, 2026

Faruqi & Faruqi, LLP Urges Regeneron Pharmaceuticals, Inc. (REGN) - The National Law Review

Aug 30, 2026
pulisher
Aug 29, 2026

Regeneron Pharmaceuticals (REGN) As Pasatru Approval Tests An Undervalued View - Yahoo Finance

Aug 29, 2026
pulisher
Aug 29, 2026

Regeneron Pharmaceuticals (REGN) Wins FDA Approval For Pasatru In Adult FOP - Yahoo Finance

Aug 29, 2026
pulisher
Aug 29, 2026

Regeneron Pharmaceuticals Inc. Buys New Stake in Parabilis Medicines, Inc. $PBLS - MarketBeat

Aug 29, 2026
pulisher
Aug 28, 2026

Regeneron Pharmaceuticals, Inc. (REGN) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before September 14, 2026 Lead Plaintiff Deadline - Eastern Progress

Aug 28, 2026
pulisher
Aug 28, 2026

Regeneron Pharmaceuticals Inc Initiates Recall of Libtayo (Cemiplimab-Rwlc) Injection, 350 Mg/7 Ml (50 Mg/Ml) For Intravenous Infusion After Dilution, Single-Dose Vial - marketscreener.com

Aug 28, 2026
pulisher
Aug 27, 2026

REGN DEADLINE: SueWallSt Reminds Regeneron Pharmaceuticals, Inc. Investors of Upcoming Securities Class Action Deadline - PR Newswire

Aug 27, 2026
pulisher
Aug 27, 2026

Regeneron Pharmaceuticals (REGN) Adjusts Course Amid Mixed Results in Melanoma Drug Trials - Yahoo Finance

Aug 27, 2026
pulisher
Aug 26, 2026

REGN Shareholder Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action LawsuitInvestors With Losses May Contact Levi & Korsinsky - PR Newswire

Aug 26, 2026
pulisher
Aug 26, 2026

Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch

Aug 26, 2026
pulisher
Aug 25, 2026

Regeneron: Why I Still See Upside After The Rally (NASDAQ:REGN) - Seeking Alpha

Aug 25, 2026
pulisher
Aug 24, 2026

REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Aug 24, 2026
pulisher
Aug 24, 2026

Regeneron Pharmaceuticals, Inc. (REGN) Stock Analysis: Exploring Growth Potential with a Robust Pipeline and Strategic Alliances - DirectorsTalk Interviews

Aug 24, 2026
pulisher
Aug 24, 2026

Levi & Korsinsky Reminds Regeneron Pharmaceuticals - GlobeNewswire

Aug 24, 2026
pulisher
Aug 21, 2026

Regeneron Pharmaceuticals (REGN) Wins Pasatru Approval, Is The Upside Already Priced In? - simplywall.st

Aug 21, 2026
pulisher
Aug 21, 2026

Did You Lose Money on Regeneron Pharmaceuticals, Inc. (REGN)? Levi & Korsinsky Urges Investors to Act Before September 14, 2026 - ACCESS Newswire

Aug 21, 2026

Regeneron Pharmaceuticals Inc Azioni (REGN) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Regeneron Pharmaceuticals Inc Azioni (REGN) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Fenimore Christopher R.
EVP Finance CFO
Aug 18 '26
Option Exercise
381.92
6,283
2,399,603
24,583
Guarini Kathryn
Director
Aug 10 '26
Option Exercise
719.37
400
287,748
1,003
Guarini Kathryn
Director
Aug 10 '26
Sale
800.00
400
320,000
603
Zoghbi Huda Y
Director
Aug 10 '26
Option Exercise
376.69
800
301,352
2,503
Zoghbi Huda Y
Director
Aug 10 '26
Sale
800.00
800
640,000
1,703
$1,033.15
price down icon 1.93%
$145.55
price down icon 2.23%
$210.02
price down icon 0.40%
ONC ONC
$358.26
price down icon 1.22%
$266.11
price up icon 0.61%
Capitalizzazione:     |  Volume (24 ore):